PA
NBSE

Perceptive Advisors’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Perceptive Advisors’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-15
Closed -$50K – 178
2014
Q4 		$50K Buy
+15
New +$46K ﹤0.01% 147

Other funds holding NBSE

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TI
Turner Investments Berwyn, Pennsylvania $134K AUM 49.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Perceptive Advisors's NBSE Position: Q1 2015 in Review

Perceptive Advisors sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q1 2015, closing a stake of 15 shares — an estimated $50K sold.

Perceptive Advisors first reported a position in NBSE in Q4 2014 and held it in 1 quarter. The position peaked at $50K in Q4 2014. 64 funds tracked by Wall St. Rank hold NBSE as of Q1 2015.

  • Perceptive Advisors reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q1 2015 after selling out during the quarter.
  • Perceptive Advisors sold 15 NeuBase Therapeutics, Inc. Common Stock shares in Q1 2015, an estimated $50K.
  • Perceptive Advisors first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q4 2014 and held it in 1 quarter.
  • Perceptive Advisors's NeuBase Therapeutics, Inc. Common Stock position peaked at $50K in Q4 2014.
  • 64 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q1 2015.

Based on Perceptive Advisors's 13F filing for Q1 2015, filed 15 May 2015.